Vaxcyte (PCVX) CFO awarded RSUs and options, surrenders shares for taxes

Rhea-AI Filing Summary

Vaxcyte, Inc. reported that President and CFO Andrew Guggenhime received equity awards and had shares withheld to cover taxes. On February 26, 2026, he was granted 44,864 shares of common stock in the form of RSUs and 74,993 stock options. On February 28 and March 2, 2026, a total of 1,907 shares of common stock were surrendered to the company to satisfy tax withholding on RSU vesting. He also reports indirect ownership of 61,850 shares held by ALG 2025 GRAT HOLDINGS LLC, a grantor retained annuity trust for which he is annuitant and trustee.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider GUGGENHIME ANDREW

Role PRESIDENT AND CFO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,009	$61.98	$63K
Tax Withholding	Common Stock	898	$61.98	$56K
Grant/Award	Stock Option (right to buy)	74,993	$0.00	--
Grant/Award	Common Stock	44,864	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 105,416 shares (Direct); Stock Option (right to buy) — 74,993 shares (Direct); Common Stock — 61,850 shares (Indirect, See Footnote)

Footnotes (1)

1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee. 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GUGGENHIME ANDREW

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		44,864(1)	A	$0	107,323	D
Common Stock	02/28/2026		F		898(2)	D	$61.98	106,425	D
Common Stock	03/02/2026		F		1,009(2)	D	$61.98	105,416	D
Common Stock								61,850	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$60	02/26/2026		A		74,993		(4)	02/26/2036	Common Stock	74,993	$0	74,993	D

Explanation of Responses:

1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

2. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

3. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.

4. 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Remarks:

	Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Vaxcyte (PCVX) report for Andrew Guggenhime?

Vaxcyte reported equity awards and tax-related share surrenders for Andrew Guggenhime. He received 44,864 RSU-based common shares, 74,993 stock options, and surrendered a total of 1,907 shares to cover tax withholding obligations on vested RSUs.

How many Vaxcyte (PCVX) RSUs were granted to Andrew Guggenhime and how do they vest?

Andrew Guggenhime was granted 44,864 RSU-based common shares. One quarter of these vest on September 7, 2026, and one eighth vests every six months thereafter, contingent on his continued service with Vaxcyte through each applicable vesting date.

What stock option grant did Andrew Guggenhime receive from Vaxcyte (PCVX)?

He received a grant of 74,993 stock options with a right to buy Vaxcyte common stock. One forty-eighth of the options vest on March 26, 2026, and one forty-eighth vests monthly thereafter, subject to his continuous service with the company.

Were any of Andrew Guggenhime’s Vaxcyte (PCVX) share dispositions open-market sales?

The reported dispositions were not open-market sales. A total of 1,907 shares of common stock were surrendered back to Vaxcyte at $61.98 per share solely to satisfy applicable tax withholding obligations upon the vesting of RSUs.

What indirect ownership in Vaxcyte (PCVX) does Andrew Guggenhime report?

He reports indirect ownership of 61,850 Vaxcyte common shares. These shares are held by ALG 2025 GRAT HOLDINGS LLC, whose limited liability company interest is owned by a grantor retained annuity trust where he serves as both annuitant and trustee.

How many Vaxcyte (PCVX) shares does Andrew Guggenhime hold directly after these transactions?

After the reported transactions, Andrew Guggenhime directly holds 105,416 shares of Vaxcyte common stock. This figure reflects his ownership following the RSU grants, option grant, and the surrender of shares to cover tax withholding obligations on vested RSUs.